Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy. Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell™ technology. WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat ...